Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
clinical trials
drugs
life sciences
3
×
national blog main
3
×
rna interference
aminolevulinic acid
boston
boston top stories
givosiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
biotech
evercore isi
evolocumab
fda
heart attack
inclisiran
joseph swartz
medicines co.
new york
new york blog main
new york top stories
onpattro
patisiran
paul matteis
pcsk9 inhibitors
regeneron pharmaceuticals
stifel financial
stroke
svb leerink
umer raffat
What
alnylam
drug
pharmaceuticals
3
×
rna
3
×
data
interference
medicine
new
rnai
second
seek
speedy
ago
approval
based
cholesterol
cleared
evidence
far
fda
heart
indicated
lasting
long
looms
lowering
market
medco
medicines
nasdaq
nod
ok
partner
presented
quick
reckoning
supporting
term
touts
use
Language
Current search:
rna
×
pharmaceuticals
×
" life sciences "
×
" national blog main "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug